Dr. Sue Eckhardt, MD

NPI: 1043300726
Total Payments
$419,765
2024 Payments
$392,599
Companies
5
Transactions
51

Payment Breakdown by Category

Other$376,119 (89.6%)
Consulting$29,360 (7.0%)
Travel$9,783 (2.3%)
Research$2,921 (0.7%)
Food & Beverage$1,583 (0.4%)

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $376,119 5 89.6%
Consulting Fee $29,360 6 7.0%
Travel and Lodging $9,783 20 2.3%
Unspecified $2,921 1 0.7%
Food and Beverage $1,583 19 0.4%

Payments by Type

General
$416,845
50 transactions
Research
$2,921
1 transactions

Top Paying Companies

Company Total Records Latest Year
Exelixis Inc. $379,510 15 $0 (2024)
Amgen Inc. $25,111 20 $0 (2024)
Merck Sharp & Dohme Corporation $9,984 13 $0 (2019)
F. Hoffmann-La Roche AG $5,141 2 $0 (2020)
Boston Scientific Corporation $19.15 1 $0 (2018)

Payment History by Year

Year Amount Transactions Top Company
2024 $392,599 27 Exelixis Inc. ($379,510)
2022 $12,022 8 Amgen Inc. ($12,022)
2020 $2,921 1 F. Hoffmann-La Roche AG ($2,921)
2019 $9,972 12 Merck Sharp & Dohme Corporation ($9,972)
2018 $19.15 1 Boston Scientific Corporation ($19.15)
2017 $2,232 2 F. Hoffmann-La Roche AG ($2,220)

All Payment Transactions

51 individual payment records from CMS Open Payments — Page 1 of 3

Date Company Product Nature Form Amount Type
11/18/2024 Exelixis Inc. Travel and Lodging In-kind items and services $864.90 General
11/18/2024 Exelixis Inc. Travel and Lodging In-kind items and services $759.89 General
10/09/2024 Exelixis Inc. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $21,000.00 General
09/18/2024 Exelixis Inc. Travel and Lodging Cash or cash equivalent $76.27 General
09/10/2024 Amgen Inc. Consulting Fee Cash or cash equivalent $5,488.00 General
09/10/2024 Amgen Inc. Consulting Fee Cash or cash equivalent $5,488.00 General
09/10/2024 Amgen Inc. Travel and Lodging Cash or cash equivalent $90.00 General
09/06/2024 Exelixis Inc. Travel and Lodging In-kind items and services $173.53 General
08/09/2024 Amgen Inc. Travel and Lodging In-kind items and services $121.27 General
08/09/2024 Amgen Inc. Food and Beverage In-kind items and services $22.00 General
08/09/2024 Amgen Inc. Food and Beverage In-kind items and services $17.56 General
08/09/2024 Amgen Inc. Food and Beverage In-kind items and services $10.54 General
08/09/2024 Amgen Inc. Food and Beverage In-kind items and services $8.76 General
08/08/2024 Amgen Inc. Travel and Lodging In-kind items and services $263.54 General
08/08/2024 Amgen Inc. Travel and Lodging In-kind items and services $212.05 General
08/08/2024 Amgen Inc. Food and Beverage In-kind items and services $58.98 General
07/31/2024 Exelixis Inc. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $21,000.00 General
07/31/2024 Exelixis Inc. Travel and Lodging In-kind items and services $967.70 General
07/26/2024 Amgen Inc. Travel and Lodging In-kind items and services $1,308.22 General
05/09/2024 Exelixis Inc. Food and Beverage In-kind items and services $328.65 General
05/09/2024 Exelixis Inc. Food and Beverage In-kind items and services $169.74 General
05/08/2024 Exelixis Inc. Food and Beverage In-kind items and services $262.53 General
05/08/2024 Exelixis Inc. Food and Beverage In-kind items and services $169.87 General
04/24/2024 Exelixis Inc. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $21,000.00 General
03/25/2024 Exelixis Inc. Travel and Lodging In-kind items and services $852.31 General

Research Studies & Clinical Trials

Study Name Company Amount Records
A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY ADMINISTERED WITH BEVACIZUMAB ANDOR CHEMOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS F. Hoffmann-La Roche AG $2,921 1

About Dr. Sue Eckhardt, MD

Dr. Sue Eckhardt, MD is a Medical Oncology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043300726.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sue Eckhardt, MD has received a total of $419,765 in payments from pharmaceutical and medical device companies, with $392,599 received in 2024. These payments were reported across 51 transactions from 5 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($376,119).

Practice Information

  • Specialty Medical Oncology
  • Location Austin, TX
  • Active Since 10/13/2006
  • Last Updated 04/16/2019
  • Taxonomy Code 207RX0202X
  • Entity Type Individual
  • NPI Number 1043300726

Products in Payments

  • Tecentriq (Biological) $2,921
  • Avastin (Biological) $2,220
  • SPECTRA WAVEWRITER (Device) $19.15

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Medical Oncology Doctors in Austin